Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab in Second Line Setting for CLDN18.2 Positive Gastro-esophageal Adenocarcinoma
NCT06962137Phase 2Recruiting
- Sponsor
- UZ Leuven
- Start
- Dec 2025
- Primary completion
- Dec 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zolbetuximab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by UZ Leuven. Started Dec 2025; status: recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06962137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06962137.